

# Smallpox Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/SF91084BB014EN.html>

Date: March 2022

Pages: 55

Price: US\$ 2,000.00 (Single User License)

ID: SF91084BB014EN

## Abstracts

Smallpox Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Smallpox - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Smallpox (Infectious Disease) pipeline landscape.

Smallpox is an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain and vomiting. This is followed by the development of rashes on the face, hands, forearms and the trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat. Treatment includes medications such as antiviral and lifestyle modification.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Smallpox - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Smallpox (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the

therapeutics, its complete research and development history and latest news and press releases.

The Smallpox (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 1, 7 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Smallpox (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Smallpox (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Smallpox (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Smallpox (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Smallpox (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Smallpox (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Smallpox (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Smallpox (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Smallpox - Overview
- Smallpox - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Smallpox - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Smallpox - Companies Involved in Therapeutics Development
- AlphaVax Inc
- Bavarian Nordic A/S
- BioFactura Inc
- EpiVax Inc
- HK inno.N Corp
- SIGA Technologies Inc
- Tonix Pharmaceuticals Holding Corp
- Viraze
- Smallpox - Drug Profiles
- CJ-40011 - Drug Profile
- Product Description
- Mechanism Of Action
- Jynneos - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Monoclonal Antibody for Smallpox - Drug Profile
- Product Description
- Mechanism Of Action
- NIOCH-14 - Drug Profile
- Product Description
- Mechanism Of Action

smallpox vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

smallpox vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

smallpox vaccine - Drug Profile

Product Description

Mechanism Of Action

ST-357 - Drug Profile

Product Description

Mechanism Of Action

tecovirimat - Drug Profile

Product Description

Mechanism Of Action

History of Events

TNX-1200 - Drug Profile

Product Description

Mechanism Of Action

TNX-1800 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TNX-801 - Drug Profile

Product Description

Mechanism Of Action

History of Events

VIR-002 - Drug Profile

Product Description

Mechanism Of Action

Smallpox - Dormant Projects

Smallpox - Discontinued Products

Smallpox - Product Development Milestones

Featured News & Press Releases

Mar 02, 2022: SIGA announces start of TPOXX post-exposure prophylactic (“PEP”) clinical trials

Jan 10, 2022: SIGA Technologies receives approval from the European Medicines

Agency for tecovirimat

Dec 01, 2021: SIGA announces Health Canada regulatory approval of oral TPOXX

Nov 16, 2021: European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) recommends approval of tecovirimat

Sep 07, 2021: SIGA CEO to speak at NCT USA Conference September 8, 2021

Jun 11, 2021: Bavarian Nordic assists public health England in response to new cases of Monkeypox

May 04, 2021: SIGA announces New Drug Application filing with FDA for intravenous formulation of TPOXX

Mar 22, 2021: Bavarian nordic receives additional smallpox vaccine order from the Canadian government

Feb 19, 2021: BioFactura funded \$13 million contract option for its smallpox biodefense therapeutic

Jan 13, 2021: SIGA Announces Public Health Agency of Canada contract award to purchase up to approximately \$33 million of oral TPOXX

Jan 05, 2021: Bavarian Nordic to supply smallpox vaccines to three European countries

Dec 16, 2020: Bavarian Nordic secures second part of Smallpox Vaccine order from the U.S. Government

Dec 04, 2020: Vaccine genome researchers report 99.7% colinear identity between a U.S. civil war era smallpox vaccine and horsepox virus

Nov 12, 2020: SIGA Technologies Chief Scientific Officer to participate at NCT Asia Virtual Conference

Oct 08, 2020: SIGA announces Public Health Agency of Canada intent to purchase up to 33,300 courses of Oral TPOXX

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Smallpox, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Smallpox - Pipeline by AlphaVax Inc, 2022  
Smallpox - Pipeline by Bavarian Nordic A/S, 2022  
Smallpox - Pipeline by BioFactura Inc, 2022  
Smallpox - Pipeline by EpiVax Inc, 2022  
Smallpox - Pipeline by HK inno.N Corp, 2022  
Smallpox - Pipeline by SIGA Technologies Inc, 2022  
Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022  
Smallpox - Pipeline by Viraze, 2022  
Smallpox - Dormant Projects, 2022  
Smallpox - Dormant Projects, 2022 (Contd..1)  
Smallpox - Discontinued Products, 2022



## List Of Figures

### LIST OF FIGURES

- Number of Products under Development for Smallpox, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022

## I would like to order

Product name: Smallpox Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/SF91084BB014EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SF91084BB014EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

